Liftstream is an executive search recruitment company in the life sciences sector
Jazz Pharmaceuticals to acquire rare disease company Gentium
Authored by James Sheppard
Shire expands rare disease reach with Viropharma Purchase
Authored by James Sheppard
immatics bags $46m for Phase III cancer vaccine
Authored by James Sheppard
DRI Capital raises third fund for royalty investments
Authored by Karl Simpson
Cubist augments position in antibiotic market with Trius and Optimer buys
Authored by Paul Foster
GSK wins big with Two FDA approvals in Melanoma
Authored by James Sheppard
Allergan Adds Migraine Treatment with purchase of MAP Pharmaceuticals
Allergan today (23/1/13) said that it would buy US based MAP Pharmaceuticals in a $958m acquisition. Allergan is purchasing MAP Pharmaceuticals in cash and has paid a 60% premium on the closing share price of MAP. Allergan expects the deal to dilute 2013 earnings by about 7 cents a share and begin to add revenue in H2 2014. The purchase follows on from a collaboration agreement Allergan and MAP made in January 2011 to co-promote Levadex in the US and Canada.
Rare Disease Year in Review
This year has been a tumultuous year for the rare diseases market with a number of significant news stories revolving around M&A rumours, regulatory approvals, IPO’s, investments and partnering agreements. Liftstream takes a look at these events: